Personalizing Prophylaxis for Hemophilia A and B: A New Era in Treatment and Management - a podcast by ReachMD

CME credits: 0.50

Valid until: 25-02-2022

Claim your CME credit at https://reachmd.com/programs/cme/personalizing-prophylaxis-hemophilia-and-b-new-era-treatment-and-management/12152/

Hemophilia A and hemophilia B are congenital X-linked bleeding disorders caused by deficiency of coagulation factor VIII (FVIII) and IX (FIX). While the life expectancy of patients with hemophilia has dramatically increased over the past several decades, the hemophilia population still faces unique challenges that require appropriate use of effective strategies. The preferred treatment option for patients with hemophilia is replacement therapy. Prophylaxis with standard recombinant factor requires regular intravenous infusion at least two (FIX) to three (FVIII) times a week. Recombinant FVIII and FIX products with an extended half-life are currently available and newer strategies are on the horizon. With reported mean half-life extensions of 1.5–1.8 times that of standard products for FVIII and 3–5 times that of standard products for FIX, these therapies have the potential to address and individualize the needs of patients.

Click here to access patient information on hemophilia from the CDC.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD